TRB-051 / Eli Lilly, TRex Bio - LARVOL DELTA

TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases (Businesswire) - "TRex Bio, Inc...announced that collaboration partner Eli Lilly and Company ('Lilly') has initiated a Phase 1 first-in-human study of TRB-051, a modulator of immune effector cells, for treatment of autoimmune and inflammatory diseases. The program is one of three under the research collaboration and exclusive worldwide license agreement between TRexBio and Lilly, which leverages TRexBio’s proprietary Deep Biology platform to identify and develop novel therapies for the treatment of immune-mediated diseases. Pursuant to the agreement, TRexBio has earned a double-digit million dollar milestone payment and is eligible to receive more than $1.1 billion on achievement of certain development, regulatory, and commercial milestones across partnered programs....TRB-061 is currently in IND enabling studies, and the company anticipates advancing the program into the clinic in the first half of 2025."

New trial • Trial status • Immunology